Wednesday, July 8, 2026

biotech · Chronic Peripheral Neuropathy Pain in Diabetics · Diabetic Peripheral Neuropathy · XTLB

XTL BIOPHARMACEUTICALS

XTL BIOPHARMACEUTICALS clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Raanana, USA HQ
1993 Founded
3 Employees
Public company Type
XTLB · NYSE Ticker
Company details
Status
Public
HQ
Raanana, USA
Founded
1993
Employees
3
Programs
4
Drugs
1
Patents
7
Intelligence · Clinical Programs

XTL BIOPHARMACEUTICALS projects

2 ClinicalTrials.gov programs sponsored by XTL BIOPHARMACEUTICALS.

XTL BIOPHARMACEUTICALS has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Bicifadine

    XTL BIOPHARMACEUTICALS LTD

    Chronic Peripheral Neuropathy Pain in Diabetics

    phase 2 small molecule terminated

    1 trial
  2. Bicifadine

    XTL BIOPHARMACEUTICALS LTD

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does XTL BIOPHARMACEUTICALS have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.